Endersby C A, Brown E G, Perelman M S
International Drug Surveillance Department, Glaxo Group Research, Middlesex, U.K.
J Cardiovasc Pharmacol. 1991;17 Suppl 4:S45-7.
The clinical safety of the new dihydropyridine calcium antagonist lacidipine was assessed in 14 clinical trials, including 1,372 patients treated with lacidipine and 687 treated with an alternative antihypertensive agent. The type and incidence of adverse events seen with lacidipine were characteristic of this class of drug, being mainly those associated with the pharmacologic effect of vasodilation, but with a lower incidence of edema than seen with nifedipine. There were no unexpected adverse effects. Hence, lacidipine is likely to be well accepted in general clinical use. Furthermore, as it has the advantages of a long duration of action and once-daily dosage, the benefit/risk ratio indicates that lacidipine is a suitable agent for the first-line treatment of hypertension across a wide range of patients.
在14项临床试验中对新型二氢吡啶类钙拮抗剂拉西地平的临床安全性进行了评估，其中1372例患者接受拉西地平治疗，687例患者接受其他抗高血压药物治疗。拉西地平所致不良事件的类型和发生率具有此类药物的特征，主要是与血管舒张药理作用相关的不良事件，但水肿发生率低于硝苯地平。未出现意外不良反应。因此，拉西地平在一般临床应用中可能会被广泛接受。此外，由于它具有作用持续时间长和每日一次给药的优点，效益/风险比表明拉西地平是各类患者一线治疗高血压的合适药物。
